Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Chronic prurigo: Insufficient disease control in spite of high healthcare usage.
Pereira MP, Weisshaar E, Halvorsen JA, Wallengren J, Legat FJ, Garcovich S, Savk E, Reich A, Bozek A, Lvov A, Bobko S, Metz M, Streit M, Misery L, Brenaut E, Serra-Baldrich E, Gonçalo M, Szepietowski JC, Augustin M, Nau T, Zeidler C, Ständer S. Pereira MP, et al. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):e808-e812. doi: 10.1111/jdv.18903. Epub 2023 Feb 21. J Eur Acad Dermatol Venereol. 2023. PMID: 36682045 No abstract available.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
Yosipovitch G, Lio PA, Rosmarin D, Serra-Baldrich E, Legat FJ, Casillas M, Pierce E, Liu Z, Sun L, Elmaraghy H, Ständer S. Yosipovitch G, et al. Br J Dermatol. 2024 Jan 23;190(2):289-291. doi: 10.1093/bjd/ljad435. Br J Dermatol. 2024. PMID: 37939793 Clinical Trial. No abstract available.
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crépy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S; trial investigators. Bissonnette R, et al. Among authors: serra baldrich e. Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18. Lancet. 2024. PMID: 39033766 Clinical Trial.
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan-Cox M, Garcia Gil E, Silverberg JI. Blauvelt A, et al. Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022. Br J Dermatol. 2023. PMID: 36994947 Clinical Trial.
First update of the living European guideline (EuroGuiDerm) on atopic eczema.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen-Zaech S, Deleuran M, Dittmann M, Fosse N, Gáspár K, Gerbens LAA, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Rehbinder EM, Ring J, Rossi M, Roxburgh C, Serra-Baldrich E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1283-e1287. doi: 10.1111/jdv.19269. Epub 2023 Jul 17. J Eur Acad Dermatol Venereol. 2023. PMID: 37328919 Free article. No abstract available.
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results.
Pereyra-Rodríguez JJ, Herranz P, Ruiz-Villaverde R, Elosua-González M, Galán-Gutiérrez M, Figueras-Nart I, Miquel J, de la Cueva P, Serra-Baldrich E, Munera-Campos M, Melé-Ninot G, Expósito-Serrano V, Perez B, Serrano A, Ortiz de Frutos JF, Armario-Hita JC. Pereyra-Rodríguez JJ, et al. Clin Exp Dermatol. 2023 Aug 25;48(9):991-997. doi: 10.1093/ced/llad153. Clin Exp Dermatol. 2023. PMID: 37098171
Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study.
Armario-Hita JC, Pereyra-Rodriguez JJ, González-Quesada A, Herranz P, Suarez R, Galan-Gutiérrez M, Rodríguez-Serna M, Ortiz de Frutos J, Carrascosa JM, Serra-Baldrich E, Ara-Martin M, Figueras-Nart I, Silvestre JF, Zaragoza-Ninet V, Ruiz-Villaverde R. Armario-Hita JC, et al. Among authors: serra baldrich e. Int J Dermatol. 2024 Nov;63(11):e289-e295. doi: 10.1111/ijd.17344. Epub 2024 Jun 21. Int J Dermatol. 2024. PMID: 39425593
126 results